Skip to main content
OpenTrials
Completed

NCT Number: NCT00997269

Benefit of CoQ-10 in Patients on Statins

This study will investigate whether a supplement called co-enzyme Q10 can help ease or eliminate some of the side effects that result from taking statin medications. These side effects include muscle pain, fatigue or muscle cramping.

Completed

Looking for future studies?

Notify Me

Key information

Age range

21 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Stony Brook University GCRC

Stony Brook, New York, 11794, United States

About this study

Specific Aim 1: to demonstrate that supplementation with coQ10 in patients treated with statins ameliorates symptoms of muscle pain and fatigue and improves energy metabolism and muscle function.

This objective will be achieved in a randomized, placebo-controlled double blind trial by assessing the degree of muscle symptoms and interference of pain with daily activities, aerobic capacity, and muscle function before and after supplementation with either coQ10 or placebo in groups of statin-treated subjects.

Specific Aim 2: to examine changes at a molecular/cellular level that are associated with improved pain and muscle function in statin-treated subjects supplemented with coQ10.

This aim will be addressed by analyzing muscle biopsies taken from statin-treated patients before and after supplementation with coQ10 or placebo.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult men and women 21 years and older taking statin medications for hyperlipidemia under the current National Cholesterol Education Program guidelines (NCEP III) and complaining of myopathic symptoms.

Exclusion criteria

  • diagnosis of cancer;
  • acute illness of any sort;
  • hemoglobin less than 12,
  • creatinine greater than 1.5 mg/dl;
  • liver dysfunction as evidenced by elevations in transaminases 3-fold higher than upper limit of normal;
  • use of certain medications or nutritional supplements within the past month;
  • untreated hypertension (diastolic BP> 100 mm HG);
  • diagnosis of diabetes mellitus (fasting blood glucose > 126 mg/dl);
  • untreated hypothyroidism;
  • overt congestive heart failure (by physical exam);
  • active inflammatory diseases such as rheumatoid arthritis, lupus, etc.,
  • bleeding disorders;
  • history of adverse reactions besides myopathy associated with the use of statins;
  • any previous adverse reaction to coQ10 or to multivitamin supplements containing coQ10;
  • plasma CPK levels > 3 times the upper normal limit; OR
  • congenital myopathies and/or neuromuscular degenerative diseases.

Treatment and study plan

Co-enzyme Q-10

Dietary Supplement

Patients will be supplemented with 300 mg of CoQ-10 1 time daily for one month

Other names: ubiquinone

Placebo

Dietary Supplement

Patients will be supplemented with CoQ-10 placebo 1 time daily for one month

Primary outcomes

  1. Pain scores should be reduced

    Time frame: 8 weeks

Sponsors and collaborators

Lead sponsor

Stony Brook University

Other

Registry information

Acronym: CoQ-10

Important dates

Study start
2009
Primary completion
2014
Study completion
2014
First posted
Oct 19, 2009
Registry last updated
May 2, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.